|
Get ready for Tomorrow (Oct 15th) at 7 am EST! Exciting news! A small-cap biotech firm on the NYSE is set to revolutionize antiviral medicine with its groundbreaking nanomedicine, targeting viruses like RSV and COVID-19. With a market potential of $1.8 to $8 billion, their lead drug has outperformed top antiviral treatments in clinical trials As the company prepares for Phase II trials for RSV, this could be a significant opportunity for investors.Stay tuned for more on this potential game-changer! This message is a PAID ADVERTISEMENT for NanoViricides, Inc. (NYSE American: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $10,000 for multiple Dedicated Email Sends, Newsletter Sponsorship, and Banner Display Ads between October 15, 2024 and October 21, 2024.. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc. (NYSE American: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC). StockEarnings, Inc |
No comments:
Post a Comment